New Targets for the Treatment of Hypertension and Associated Diseases

William B. Campbell, PhD, Professor and Chairman of the Department of Pharmacology and Toxicology at the Medical College of Wisconsin received his PhD from the University of Texas Health Science Center in Dallas. After post-doctoral work and another year as an instructor at the Medical College of Wisconsin he moved to the Department of Pharmacology at the University of Texas Southwestern Medical Center where he would eventually become full Professor of Pharmacology. In 1992 he became Chair of Pharmacology at the Medical College of Wisconsin. For the past 30 years, Dr. Campbell has been investigating the contribution of various vasoactive agents that regulate blood pressure. His studies on endothelium-derived factors that regulate blood pressure and vascular tone identified the major vasoactive metabolites of arachidonic acid that are produced by the vascular endothelium. He has consistently made major contributions in research, teaching and service to various institutions and to the scientific community in general. Dr. Campbell has received numerous awards for his research including the Research Career Development Award from the National Institutes of Health. In 2006, he received the Novartis Award for Hypertension Research, the most prestigious award in the world in the area of hypertension research. He has received the Outstanding Mentor and Teaching Award from the Medical College of Wisconsin. John D. Imig, Ph.D. is a Professor and Director Drug Discovery at the Medical College of Wisconsin. Dr. Imig has received a number of awards for his research in cardiovascular and renal physiology included the prestigious Established Investigator Award from the American Heart Association. Dr. Imig has authored over 200 publications related to the antihypertensive properties and renal and cardiovascular protective properties of angiotensin receptor antagonists and soluble epoxide hydrolase inhibitors.

1. The CYP/20-HETE/GPR75 axis in hypertension Ghezal Froogh, Victor Garcia and Michal L. Schwartzman 2. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury John D Imig 3. Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulation Annika A. Jüttner, A.H. Jan Danser and Anton J.M. Roks 4. Sphingosine-1-phosphate and sphingosine-1-phosphate receptors in the cardiovascular system: Pharmacology and clinical implications Simona Federica Spampinato, Maria Angela Sortino and Salvatore Salomone 5. Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease Dominique Brown, Heather Alcala, Peter Oelschlaeger and Bradley T. Andresen 6. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension Prasad Chunduri, Shrey A. Patel and Scott P. Levick 7. Cardiovascular effects of GLP-1 receptor agonism Raymond J. Winquist and Valentin K. Gribkoff 8. ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease HaiFeng Yang and Raouf A. Khalil 9. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Roberto Levi